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Exposure to blast overpressure waves is implicated as the major cause of ocular injuries
and resultant visual dysfunction in veterans involved in recent combat operations. No
effective therapeutic strategies have been developed so far for blast-induced ocular
dysfunction. Lysophosphatidic acid (LPA) is a bioactive phospholipid generated by
activated platelets, astrocytes, choroidal plexus cells, and microglia and is reported
to play major roles in stimulating inflammatory processes. The levels of LPA in the
cerebrospinal fluid have been reported to increase acutely in patients with traumatic
brain injury (TBI) as well as in a controlled cortical impact (CCI) TBI model in mice. In
the present study, we have evaluated the efficacy of a single intravenous administration
of a monoclonal LPA antibody (25 mg/kg) given at 1 h post-blast for protection against
injuries to the retina and associated ocular dysfunctions. Our results show that a single
19 psi blast exposure significantly increased the levels of several species of LPA in
blood plasma at 1 and 4 h post-blast. The anti-LPA antibody treatment significantly
decreased glial cell activation and preserved neuronal cell morphology in the retina on
day 8 after blast exposure. Optokinetic measurements indicated that anti-LPA antibody
treatment significantly improved visual acuity in both eyes on days 2 and 6 post-blast
exposure. Anti-LPA antibody treatment significantly increased rod photoreceptor and
bipolar neuronal cell signaling in both eyes on day 7 post-blast exposure. These results
suggest that blast exposure triggers release of LPAs, which play a major role promoting
blast-induced ocular injuries, and that a single early administration of anti-LPA antibodies
provides significant protection.
Keywords: blast exposure, eye injury, ocular dysfunction, lysophosphatidic acid, anti-LPA antibody, rat, retina
INTRODUCTION
Exposure to blast overpressure waves is implicated as the major cause of ocular injuries and
resultant visual dysfunction in veterans involved in recent combat operations (1). Although
personnel are issued protective goggles, eye injuries nevertheless occur due to non-compliance,
blast wave penetration through goggles, or goggles being dislodged (2). Between 2006 and 2009,
20 (43%) of 46 combat-veteran in-patients with blast-induced traumatic brain injury (TBI) had
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significant closed-eye injuries (3). Brain visual signal processing
centers (e.g. optic tracts) are also possibly directly perturbed
by the blast waves (4). Both clinical and preclinical studies
evaluating effects of low-level single and repeated blast exposures
have shown significant pathological changes in the ocular
system (5, 6). Despite the difficult lifelong disability that loss
of vision represents, there have been only a few animal studies
assessing blast injuries to the eyes and visual system (7–12) and
very few have evaluated drug therapies (13–17). No effective
countermeasure has been developed to date.
Using a compressed air-driven shock tube, it has been shown
that a single blast exposure in rats can induce cellular apoptosis
in the optic nerve, the ganglion layer, and inner nuclear layers of
the retina (18–20). A follow-up study demonstrated that single as
well as repeated low-level blast exposures trigger increases in the
cellular apoptosis marker, caspase-3, and the pro-inflammatory
marker, cluster of differentiation 68 (CD68), in the optic nerve
(6). Single and repeated low-level blast exposures also greatly
increased glial fibrillary acidic protein (GFAP) in the retina (6).
Using a blast simulation in which an air-jet is generated by a
modified paintball gun that is pointed directly at the eyes of mice,
it was found that the exposure caused retinal detachments, large
retinal pigment epithelium vacuoles, regional rod photoreceptor
cell death, and glial cell reactivity (21). In that study, immune
infiltrate was detected throughout the eyes after the insult. These
results suggest that blast exposure caused cellular inflammation
in the peripheral and central ocular system and therapies
which can counter these pro-inflammatory responses might be
effective in protecting the ocular system. Glial cell activation
and hyperphosphorylation of Tau protein, which are known to
induce neuronal degeneration, were also observed in the retina
up to several days after blast exposure (11). Thus, therapies which
can inhibit the hyperphosphorylation of Tau protein might also
be protective against retinal neurodegeneration. Our laboratory
has also shown similar acute and sub-acute changes in ocular
functions and retina and brain visual signal processing center
(i.e., optic tract) pathologies in rats after single blast exposure
using a compressed air-driven shock tube (12).
Lysophosphatidic acid (LPA; 1-acyl-sn-glycerol 3-phosphate),
which is reported to play major roles in stimulating inflammatory
processes (22, 23), is a bioactive metabolite of phospholipids
(i.e., phosphatidyl choline) generated by the sequential actions
of phospholipase A2 and then lysophospholipase D (autotaxin)
within activated platelets, astrocytes, choroidal plexus cells
and microglia in response to injuries. LPA species with both
saturated fatty acids and polyunsaturated fatty acids have
been identified in various biological fluids including plasma,
serum and cerebrospinal fluid (CSF). LPA can mediate a
series of signaling events (e.g. adenylate cyclase inhibition and
endoplasmic reticulum Ca2+ mobilization) through specific G-
protein coupled LPA receptors. Following central nervous system
(CNS) injury, ischemia, or related events that damage the blood-
brain barrier, LPA-like activity is increased within the CSF
and LPA receptor modulation occurs in different regions of
the brain (24, 25). In addition to inducing neuropathic pain
and demyelination, LPA can stimulate astrocytic proliferation,
inflammation and, depending upon its concentration, can
promote death of neurons by apoptosis or by necrosis at high
levels (26–32). LPA is reported to be involved in stimulating Tau
protein phosphorylation through activation of glycogen synthase
kinase-3β and protein kinase A leading to neurite retraction in
multiple neuronal cell lines (33, 34).
No studies have been carried out to determine the
involvement of LPA in blast wave induced eye injuries;
however, evidence for a negative impact of LPA on retinal health
is strong. Intravitreal injection of LPA leads to a decreased
microvasculature in the retinas of rat pups (35). Additionally,
using retinal ganglion cells in culture, it has been shown that
LPA receptor1 is likely involved in retinal cell degeneration in
hyper-oxygenation induced retinopathy of prematurity (36).
In an embryonic chick visual system model, introduction of
LPA causes a dose-dependent growth cone collapse of cultured
retinal neurons (37). Significantly elevated levels of LPAs were
detected in vitreous humor samples from the eyes of patients
with retinal vein occlusion and were positively correlated with
those of pro-inflammatory cytokines, suggesting a role of LPAs
in exacerbating secondary pathologies associated with the
condition, e.g. macular edema (38).
Increased LPA levels and differential expression of LPA
receptors have been implicated in neurotrauma and neuropathic
pain (24, 39, 40). Different LPA species were found to be elevated
in the CSF of patients with TBI unrelated to blast, due to
severe closed-head concussions (e.g. motor vehicle accidents
and falls) (24). The levels were significantly higher 24 h after
injury and returned to normal levels by day 5, the only two
time points evaluated (24). Multiple LPA species were elevated
at 3 h and returned to normal levels by 14 h in the CSF of
mice subjected to controlled cortical impact (CCI) induced
TBI, revealing that extracellular LPAs rapidly increase after
brain injury (24). Intravenous administration of the antibodies
raised against LPAs significantly improved neuropathology and
function after TBI and spinal cord injury in experimental
animals, demonstrating that the acutely increased extracellular
LPAs are deleterious to the central nervous system and that
therapeutic strategies to scavenge these LPAs can be highly
beneficial (24, 40). Likewise, intranasal administration of LPA
antibodies was found to be advantageous in an animal model
of CCI-induced TBI and reduced the symptom of mechanically
induced neuropathic pain (allodynia) (39). In the present study,
using an Advanced Blast Simulator (ABS), which generates high
fidelity blast waves closely resembling those encountered with
free field explosions, we have evaluated the efficacy of a single
intravenous administration of LPA antibodies for protection
against blast-induced ocular injuries.
MATERIALS AND METHODS
Animals
Research was conducted under an animal use protocol approved
by the Institutional Animal Care and Use Committee at Walter
Reed Army Institute of Research in a facility accredited by the
Association for the Assessment and Accreditation of Laboratory
Animal Care-International in compliance with the Animal
Welfare Act and other federal statutes and regulations relating
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to animals and experiments involving animals and adheres to
principles stated in the Guide for the Care and Use of Laboratory
Animals, NRC Publication, 2011 edition. Male Sprague Dawley
rats, 9-10 weeks old that weighed 300–350 g (Charles River
Laboratories, Wilmington, MA) were housed at 20–22◦C (12 h
light/dark cycle). Rats were given free access to nutritious rat
chow (Prolab IsoPro RMH 3000 from LabDiet, St. Louis, MO)
and water ad libitum.
Primary Blast Exposure
The ABS described previously was used for the study (41, 42). For
blast exposure, the rats were anesthetized with 4% isoflurane for
8min and secured in a longitudinal (i.e., rat facing the oncoming
shockwave) prone orientation in the test section of the ABS. To
produce moderate TBI in rats in these experiments, we used
Valmaxmembranes yielding peak positive static pressures of∼19
psi with a positive phase duration of 4–5ms. Group sizes for all
subsequent outcome measures were six animals each (n= 6).
LPA Measurements
For acute LPA measurements in the plasma, the rats were
euthanized at 1 and 4 h post-blast by drawing blood through
cardiac puncture under isoflurane anesthesia. Blood was
collected in vacutainer tubes (Becton, Dickinson and Company,
Franklin Lakes, NJ) containing ethylenediaminetetraacetic acid
as the anticoagulant and the plasma separated by centrifugation
was used for LPA measurements. The plasma samples were
stored at −80◦C until analysis. LPA measurements were carried
out as described earlier (43). Briefly, lipids were extracted
from plasma using acidified organic solvents. Different LPA
species were measured by Ultra High Performance Liquid
Chromatography (UHPLC) coupled electrospray ionization
tandem mass spectrometry using an AB Sciex 6500 Q-Trap mass
spectrometer operated in multiple reaction monitoring mode to
identify the molecules as based on their specific precursor and
product ion pairs. 17:0 LPA was used as an internal standard.
Thus, plasma LPA values were reported as µmoles per liter.
Intravenous Administration of LPA
Antibody
One hour after blast exposure, the rats were treated intravenously
with either murine anti-LPA monoclonal antibody (504B3, 25
mg/kg) or isotype-matched control antibody (IgG2b, 25 mg/kg)
under isoflurane anesthesia in sterile conditions. Sham control
rats received the same volume of saline. The antibodies were
provided by Lpath Inc. (San Diego, CA).
Visual Acuity Testing (Optokinetics)
At 2 days before (baseline) and days 2 and 6 after blast exposure,
visual acuity (VA) was tested using an optokinetics device
(OptoMotry unit; Cerebral Mechanics Inc., Alberta, Canada).
The conscious rat was placed on a pedestal inside a chamber,
where it was surrounded on all four sides by LCD monitors that
project a virtual rotating black and white bar pattern having a
starting spatial frequency at which rats should easily see, e.g. 0.04
line-cycles/degree at 100% contrast. The bar’s rotation speed was
then increased stepwise to gradually narrow the appearance of
their width. Contribution of each eye was resolved by driving the
pattern’s rotation in opposite directions, e.g. clockwise for the left
side (44). Eye pursuits were judged by reflexive movements (side
flicks) of the head, which were aligned with the direction of the
stimulus rotation. Visual acuity thresholds, as reported in line-
cycles/degree, were found by iterations of the spatial frequency of
the bar pattern, until head tracking movements were no longer
exhibited. The acuities can be measured with a 97% accuracy of
0.01. Normal young Sprague Dawley rats were reported to have
visual acuities of 0.5 (45); however, we found as they age, rats fall
closer to 0.30.
Electroretinography
At 1 day before (baseline) and days 3 and 7 after blast
exposure, retinal responses were assessed by full field flash
electroretinography (ERG) utilizing an ERG instrument (Color
Dome Full Field Ganzfeld unit; Diagnosis LLC, Lowell, MA).
Rats were dark adapted overnight (≥16 hours). While working
under photography grade red-safelights, animals were placed
under continuous 2–3% isoflurane anesthesia via a nose cone
device. Pupils were dilated with 0.5% (w/v) tropicamide and 2.5%
(w/v) phenylephrine drops in buffered saline. As an anesthetic,
each eye received proparacaine drops. Ground electrodes were
fixed to the tail, reference inside the mouth, and recording
gold-loops (contact lens style) against each eye’s cornea with a
conducting cushion of methyl cellulose solution. While under
darkness, the rat’s eyes were presented with an eight step series of
white light flashes of increasing illumination, i.e., 0.1–10 cd.s/m2
with a 5ms duration and 30–60 s interval (12). This data yielded
scotopic ERG response curves. Peak amplitudes of signaling
response wave forms, as recorded in µ-volts, were used to judge
the status of retinal rod photoreceptor (A-wave) and bipolar
(B-wave) neurons. External influences that can alter the ERGs
were minimized, such as environmental electrical noises, dark-
room light leaks, and body temperature fluctuations (46). Rats
were allowed to recover for at least 3 h under dim room light
conditions, to help prevent retina photo-damage from excessive
light stimulation until the pupillary reflex returns. Since the
ERG signals can vary among rats, the percentage change from
each experimental subject’s own baseline values were used for
measurements after blast exposure.
Histopathology and Immunohistochemistry
Paraformaldehyde (PFA) fixed eyes collected on day 8 after
blast exposures were processed by FD Neurotechnologies,
Inc. (Ellicott City, MD) for histopathological (H&E staining)
and immunohistochemical staining. Eyes were cut as a single
horizontal section through the central pupil to optic nerve
axis as described by our laboratory (12). Sections were stained
with H&E to determine gross morphological changes in the
retina, including neuronal cell loss and detachments. Distinct
neuronal layers of the entire retina (from optic nerve head to
periphery) were examined, and included ganglion, bipolar, and
rod photoreceptor cells (12). Injury scores for the retina were
ranked on an ordinal scale by highly trained reviewers blinded
to treatments using values of 1–6, representing no, slight, mild,
moderate, severe, and catastrophic levels of injury, respectively.
Frontiers in Neurology | www.frontiersin.org 3 December 2020 | Volume 11 | Article 611816
Arun et al. Antibody Therapy Against Eye Injuries
After H&E staining, the remaining paraffin sections were used
for immunohistochemistry to detect activated Müller giant glial
cells and their extensions that highly express glial fibrillary
acidic protein (GFAP) in the retina using rabbit polyclonal
antibodies against GFAP (Abcam, Cambridge,MA). Photographs
were taken using an Olympus BX61 microscope (Olympus
Corporation, Center Valley, PA) and Stereo Investigator virtual
image tool (MBF Biosciences, Williston, VT). Counting of the
number of GFAP positive cells per µm2 of field was performed
using the Image-Pro Premier software (Media Cybernetics Inc.,
Rockville, MD).
Statistical Analysis
Statistical analysis was carried out by Two-way Analysis
of Variance followed by Tukey’s post-hoc test using HSD
multiple comparisons (GraphPad Prism 6 software). Values were
expressed as mean ± standard error of the mean (SEM). Since
the histopathological scoring was done on an ordinal scale, the
groups of values were compared by Mann–Whitney U-test. A
p < 0.05 was considered as a significant difference between
treatment groups.
RESULTS
Blast Exposure Caused Acute Increases in
Multiple LPA Species in the Plasma
UHPLC and mass spectrometry analysis of the plasma revealed
an acute increase in multiple LPA species at 1 and 4 h post-
blast exposure. Statistically significant increases in LPA(18:0),
LPA(20:2), LPA(20:3), LPA(20:4), and LPA(22:4) in plasma
were observed at 1 and 4 h after single blast exposure
(Figure 1). Of these, the predominate species were LPA(18:0)
and LPA(20:4) although the fold changes after blast exposure
were most pronounced for the LPA species measured with poly
unsaturated fatty acid substituents. No statistically significant
changes in LPA levels were observed between 1 and 4
h post-blast.
Anti-LPA Antibody Treatment Improved
Visual Acuities After Blast Exposure
Visual acuity testing to assess the perception sharpness of vision
indicated that a single blast exposure significantly diminished
the ability of both eyes to discriminate between optokinetic
bar spacing patterns in control antibody-treated rats on days
2 and 6 post-blast, the two time points evaluated (Figure 2).
No significant differences in visual acuity were observed in
these rats between days 2 and 6 after blast exposure. Compared
to sham controls, the anti-LPA antibodies-treated rats showed
significantly decreased visual acuity on day 2 and not on day 6.
Compared to the isotype-matched control antibody treated rats,
the rats that received a single dose of anti-LPA antibodies had
significantly higher visual acuity values for both eyes on days 2
and 6 after blast exposure.
FIGURE 1 | LPA levels in the plasma at 1 and 4 h after blast exposure. The
values are expressed in units of µmoles/L as mean ± SEM. Levels of different
LPA species in the plasma at 1 and 4 h post-blast are compared to those of
sham (*p < 0.05; n = 6).
Anti-LPA Antibody Treated Rats Showed
Improved Retina Signaling Function After
Blast Exposure
In both eyes, as measured by ERG, A-wave and B-wave
amplitudes representative of retina neuronal cell signaling
function did not significantly change on day 3 post-blast exposure
in control and LPA antibody treated rats (Figure 3). On day 7
post-blast, both A and B-wave amplitudes were decreased in left
and right eyes of control antibody treated rats and not in anti-
LPA treated rats. Compared to control antibody treated rats, the
left eyes of anti-LPA antibody treated rats showed significantly
higher B-wave amplitudes. Compared to sham controls, the anti-
LPA antibody treated rats did not show significant changes in A
or B-wave amplitudes in either eye on days 3 or 7, the two time
points evaluated; however, in contrast to the anti-LPA antibody
treated rats, measured retina signaling responses never fell below
baseline in the sham animals.
Anti-LPA Antibodies Preserved the Retinal
Neuronal Cell Integrity After Blast
Exposure
H&E staining in the retina on day 8 indicated that a single blast
exposure affected the integrity of retina neuronal cells in the
outer nuclear layer, consisting mainly of rod photoreceptor inner
segments (Figure 4). Extensive cellular voids in the outer nuclear
layer were observed in both eyes of control antibody treated rats
after blast exposure whereas cellular integrity was preserved in
anti-LPA antibody treated rats. Compared to sham controls and
anti-LPA antibody treated rats, pathological scoring of the H&E
stained sections revealed that significant retinal degeneration was
present in both eyes of control antibody treated rats. Compared
Frontiers in Neurology | www.frontiersin.org 4 December 2020 | Volume 11 | Article 611816
Arun et al. Antibody Therapy Against Eye Injuries
FIGURE 2 | Visual acuities of left and right eyes on days 2 and 6 post-blast. The values are expressed in units of line-cycles/degree as mean ± SEM. Visual acuity
values of LPA and control antibody treated blast exposed rats were compared to those of the sham animals (*p < 0.05; n = 6). Values of LPA antibody treated rats
were compared to those of control antibody treated rats (#p < 0.05).
FIGURE 3 | ERG showing A- and B-wave amplitudes of left and right eyes on days 3 and 7 post-blast. Values are expressed in % change from their baseline (prior to
blast exposure) as mean ± SEM. A- and B-wave amplitudes of LPA and control antibody treated blast exposed rats were compared to those of the sham animals (*p
< 0.05; n = 6). Values of LPA antibody treated rats were compared to those of control antibody treated rats (#p < 0.05).
to sham controls, no significant changes in gross pathology of the
retina were observed in the anti-LPA antibody treated rats.
Glial Cell Activation in the Retina After
Blast Exposure Was Inhibited by Anti-LPA
Antibodies
Immunohistochemical evaluations on day 8 after single blast
exposure indicated that significant activation of Müller cells,
which then highly express GFAP, occurs in the retina of both
eyes of control antibody treated rats, but was not observed in
the anti-LPA antibody treated rats (Figure 5). Quantification of
glial cell activation by counting of the GFAP positive Müller cells
revealed significantly increased retinal injuries to both eyes of
control antibody treated rats after blast exposure. In contrast, no
increase in the number of activated Müller cells was observed
in the eyes of anti-LPA antibody treated rats on day 8 after
blast exposure.
DISCUSSION
The results reported in this study indicate that a single blast
exposure can disrupt the integrity of neuronal cells in the
eyes, and thus impair normal visual function, and that a single
intravenous administration of anti-LPA antibodies immediately
after blast exposure can provide significant neuroprotection
against this. Amelioration of injury was demonstrated through
post-blast improvements in visual acuity (optokinetics), retina
signal response to light (ERGs), and retina neuronal cell health
(H&E staining and GFAP immunohistochemistry) following
anti-LPA treatment. It is possible that the antibody treatment
protected other components of the ocular functional system
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FIGURE 4 | H&E stained retina sections from the left and right eyes on day 8 post-blast. (A) Representative pictures of H&E stained retina sections from left and right
eyes. Red arrows show the cellular voids in the outer nuclear layer. (B) Manual pathology scoring done on the H&E stained retina sections. The values are expressed
on ordinal scale of 1–6 as means alone since this representative of non-parametric data. Pathology scores of LPA and control antibody treated blast exposed rats
were compared to those of the sham animals (*p < 0.05; **p < 0.01; n = 6). Pathology scores of LPA antibody treated rats were compared to those of control
antibody treated rats (#p < 0.05; ##p < 0.01).
apart from the retina after blast exposure, including the optic
nerves, optic chiasm, and optic tracts; hence, further studies
are warranted to delineate the particular anatomical constituents
underlying these salutary effects. Overall, these findings have
positive implications for both military and civilian populations,
for whom the incidence of eye injuries and associated visual
dysfunctions have increased tremendously with heightened use
of improvised explosive devices and other explosive weaponries,
and for whom no effective countermeasures have yet been
developed. Risks to civilian populations extend beyond weapons
and can include blast-induced eye injuries from industrial
explosions and related domestic accidents.
As summarized in the introduction, few pre-clinical studies
have evaluated blast-induced eye injuries and associated ocular
dysfunctions (7–13) and much of this research has been
hampered by artifacts confounding the simulations of blast
employed in these studies (47). To improve the ecological validity
of blast simulations, a state-of-the-art ABS was used for the
present study. With a divergent transition section and an end
wave eliminator, the ABS eliminates the artifacts of commonly-
used constant diameter shock tubes, including end-jet pressures,
and provides a means to produce a controlled high fidelity
simulation of blast in the laboratory by generating free field
Friedlander waveforms quite comparable to field blasts using
explosives (42). No prior studies have used an ABS for evaluating
the effect of blast overpressure waves on eye injury and associated
visual dysfunctions.
Few studies have addressed the effect of LPAs on vision
(35–38) and although the levels of LPAs have been shown
to increase acutely in the CSF after brain injury (24), no
prior studies have examined levels of LPAs in the blood or
CSF after blast exposure. Figure 1 illustrates that five different
species of LPAs increased significantly in the plasma of rats
at 1 and 4 h after a single blast exposure with the greatest
fold changes seen in LPA species with polyunsaturated fatty
acids. No additional changes were observed between 1 and 4 h,
suggesting that the maximum increase occurred immediately
after blast exposure and the elevations in LPAs then persisted
for at least a few hours. Plasma LPA is predominantly generated
by the actions of autotaxin on circulating lyosphospholipids, but
platelet activation and thrombosis following blast exposuremight
contribute to this process. While LPA receptors exhibit some
selectivity for LPA species with different fatty acid chain lengths
and degrees of unsaturation (48), the biological significance
of these longer chain polyunsaturated LPA species is not well
understood. However, increases in longer chain/polyunsaturated
LPA species have been reported in other settings of inflammation,
notably in the lungs (49). We were not able to determine if
the LPA changes observed in plasma correspond with increased
levels directly inside the retina, which could possibly originate
either from activated Müller cells, or by passage from the
blood. As with the blood-brain barrier, however, the charged
mono-phosphate head group of peripherally generated LPAs
would restrict crossing the retinal-pigmented epithelium into
the retina, even if produced by nearby choroidal plexus cells,
unless there is some disruption of this barrier by the blast shock
waves. Transient openings of the blood-brain barrier for up
to 72 h do occur in rodent models of blast exposure, resulting
from disruption of the capillary endothelial cell tight junction
proteins (50). It is also possible that increased blood levels of
LPA would trigger the release of circulating pro-inflammatory
cytokines for active transport into the retina, as is known for the
brain (51), and then promote the blast-induced neuronal injury
processes. In this scenario, scavenging LPAs from blood would
be very beneficial after eye injuries. In line with this possibility,
intravenously injected anti-LPA antibodies would readily bind to
LPAs within the blood compartment but would be anticipated to
have difficulty accessing LPAs produced directly inside the retina
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FIGURE 5 | GFAP immunohistochemistry in the retina sections of both eyes on day 8 post-blast. (A) Representative pictures of retina sections from left and right eyes
after immunohistochemistry with GFAP antibodies. (B) The number of activated glial cells expressing GFAP in the retina after blast exposure and treatments. The
values are expressed in units of cells/µm2 as mean ± SEM. The number of activated glial cells of LPA and control antibody treated blast exposed rats were compared
to those of the sham animals (*p < 0.05; n = 6).
due to the antibody’s extremely large molecular size restricting
permeation unless if RPE cells were perturbed. We also were not
able to determine if the anti-LPA antibodies accumulated inside
the intraocular space, i.e., retina or vitreous humor, which would
entail the use of rather challenging experimental methods, such
as tagged antibodies as a tracer. Figure 5 reveals that glial cell
activation occurs in the retina of rats after blast exposure and that
a single injection of anti-LPA antibodies reduced the activation
of the giant Müller cells, perhaps by suppressing peripheral
cytokine production and subsequently preventing secretion of
additional LPAs. Thus, the protection of ocular injuries provided
by a single injection of anti-LPA antibodies could at least
in part be due to tempering the rapid LPA mediated pro-
inflammatory activities that promote neurodegeneration directly
inside the retina. Retinal ganglion cells express LPA-1 receptors
which are known to be involved in triggering their degeneration
from oxidative stress (36). LPAs are also able to induce Tau
protein phosphorylation, which leads to degeneration of neurons
through activation of glycogen synthase kinase-3β and protein
kinase A (33, 34).
One limitation of the present study is that we have evaluated
the efficacy of a single injection and dose of the antibodies. The
dose of 25 mg/kg was chosen since the same dose was found to
be effective against CCI induced TBI in rodents (24). Preliminary
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unpublished observations from Lpath, Inc., on a Phase 1 double-
blind, placebo-controlled, single ascending dose study to evaluate
the safety, tolerability, immunogenicity, and pharmacokinetics
of anti-LPA antibodies in healthy volunteers indicated that the
antibodies were well tolerated at all doses tested, and no serious
adverse events or dose limiting toxicities were observed. The
antibodies were administered in five different ascending dose
cohorts at 0.5, 1.0, 3.0, 10.0, and 20.0 mg/kg. Study follow-up
was completed after dosing with a single intravenous infusion in
36 subjects as planned. The pharmacokinetic profile of anti-LPA
antibodies suggests the half-life of the antibody is in the range
of 14–18 days, which gives guidance for dosing and treatment
regimens in future efficacy studies in patients with eye injuries
after blast exposure. Thus, it is likely that the half-life of the
antibodies used in the present study was sufficient to preclude
repeated dosing. However, it is possible that repeated dosing
may provide a more robust protection against blast-induced
ocular injuries and associated dysfunctions, if the sequalae of
ocular injury is prolonged. A dose-response study with repeated
administrations in rats followed by non-human primates is
warranted to determine the optimal treatment regimen and
identify potential toxicities, if any. Even with a single dosing
of anti-LPA antibodies in rats, however, we found significant
protection in retinal pathology and associated ocular functions
up to 1 week. Although a single systemic dose of the anti-LPA
antibody provided significant protection against ocular injury
in this model, future pre-clinical and clinical studies could also
involve intravitreal injections of antibodies rather than systemic
dosing. While the safety profile of systemic dosing of up to 20
mg/kg has been demonstrated in humans (unpublished data from
Lpath, Inc.), intraocular administration of therapeutic grade anti-
LPA antibodies may be beneficial in neutralizing LPAs produced
locally in the eyes after injury. The development of an effective
therapy like this will be extremely beneficial to the military
population in view of the fact that the incidence of injuries
to the ocular system have been increased tremendously in the
recent military operations due to the increased use of improvised
explosive devices.
In summary visual acuity and ERG assessments (Figures 2,
3) showed significant functional impairments for the eyes
of control rats by 3 days post-blast, but a single injection
with anti-LPA antibodies at 1 h post-exposure significantly
alleviated this impairment, suggesting that the LPA promotion
of retinal damage occurs acutely after injury and that early
removal of the surge in LPA benefits long-term recoveries.
In conclusion, blast exposure triggers the release of different
LPA species into the circulation and a single intravenous
injection of anti-LPA antibodies at 1 h post-blast exposure, by
inactivating one or more pools of LPAs, ultimately leads to a
reduction in retina glial mediated neuro-inflammation processes,
yielding significant protection against both retinal pathology and
ocular dysfunction.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included
in the article/supplementary materials, further inquiries can be
directed to the corresponding author/s.
ETHICS STATEMENT
The animal study was reviewed and approved by Institutional
Animal Care and Use Committee, Walter Reed Army institute
of Research.
AUTHOR CONTRIBUTIONS
PA, RS, and JL designed the experiments. DW and IG performed
the blast experiments. FR performed pathological analyses. JD
and AB performed ocular functional tests. AM performed LPA
analysis. PA, JD, YW, and JL analyzed the data and wrote the
manuscript. All authors contributed to the article and approved
the submitted version.
ACKNOWLEDGMENTS
This study was funded by Lpath Inc. (San Diego, CA), through a
Co-operative Research and Development Agreement (12-0234)
with Walter Reed Army Institute of Research (Silver Spring,
MD). Lpath, Inc., has since been acquired by Apollo Endosurgery
(Austin, TX). Murine anti-LPA monoclonal antibodies (504B3)
are now sold by Echelon Biosciences (Salt Lake City, UT. Product
Number: Z-P200). This research benefitted from resources and
facilities at the VAMedical Center in Lexington KY.
REFERENCES
1. Lemke S, Cockerham GC, Glynn-Milley C, Lin R, Cockerham KP. Automated
perimetry and visual dysfunction in blast-related traumatic brain injury.
Ophthalmology. (2016) 123:415–24. doi: 10.1016/j.ophtha.2015.10.003
2. Weichel ED, Colyer MH. Combat ocular trauma and systemic injury. Curr
Opin Ophthalmol. (2008) 19:519–25. doi: 10.1097/ICU.0b013e3283140e98
3. Cockerham GC, Goodrich GL, Weichel ED, Orcutt JC, Rizzo
JF, Bower KS, et al. Eye and visual function in traumatic brain
injury. J Rehabil Res Dev. (2009) 46:811–8. doi: 10.1682/JRRD.2008.
08.0109
4. Warden D. Military TBI during the Iraq and Afghanistan wars. J.Head
Trauma Rehabil. (2006) 21:398–402. doi: 10.1097/00001199-200609000-
00004
5. Capo-Aponte JE, Urosevich TG, Temme LA, Tarbett AK, Sanghera
NK. Visual dysfunctions and symptoms during the subacute stage of
blast-induced mild traumatic brain injury. Mil Med. (2012) 177:804–13.
doi: 10.7205/MILMED-D-12-00061
6. Choi JH, Greene WA, Johnson AJ, Chavko M, Cleland JM, McCarron RM,
et al. Pathophysiology of blast-induced ocular trauma in rats after repeated
exposure to low-level blast overpressure. Clin Exp Ophthalmol. (2015) 43:239–
46. doi: 10.1111/ceo.12407
7. Petras JM, Bauman RA, Elsayed NM. Visual system degeneration
induced by blast overpressure. Toxicology. (1997) 121:41–9.
doi: 10.1016/S0300-483X(97)03654-8
8. Hines-Beard J, Marchetta J, Gordon S, Chaum E, Geisert EE, Rex TS. A mouse
model of ocular blast injury that induces closed globe anterior and posterior
pole damage. Exp Eye Res. (2012) 99:63–70. doi: 10.1016/j.exer.2012.03.013
Frontiers in Neurology | www.frontiersin.org 8 December 2020 | Volume 11 | Article 611816
Arun et al. Antibody Therapy Against Eye Injuries
9. Mohan K, Kecova H, Hernandez-Merino E, Kardon RH, Harper MM.
Retinal ganglion cell damage in an experimental rodent model of blast-
mediated traumatic brain injury. Invest Ophthalmol Vis Sci. (2013) 54:3440–
50. doi: 10.1167/iovs.12-11522
10. Zou YY, Kan EM, Lu J, Ng KC, Tan MH, Yao L, et al. Primary blast injury-
induced lesions in the retina of adult rats. J Neuroinflammation. (2013) 10:79.
doi: 10.1186/1742-2094-10-79
11. Mammadova N, Ghaisas S, Zenitsky G, Sakaguchi DS, Kanthasamy AG,
Greenlee JJ, et al. Lasting Retinal Injury in a Mouse Model of Blast-
Induced Trauma.Am J Pathol. (2017) 187:1459–72. doi: 10.1016/j.ajpath.2017.
03.005
12. DeMar J, Sharrow K, Hill M, Berman J, Oliver T, Long J. Effects of primary
blast overpressure on retina and optic tract in rats. Front Neurol. (2016) 7:59.
doi: 10.3389/fneur.2016.00059
13. Jiang Y, Liu L, Pagadala J, Miller DD, Steinle JJ. Compound 49b protects
against blast-induced retinal injury. J Neuroinflammation. (2013) 10:96.
doi: 10.1186/1742-2094-10-96
14. Dutca LM, Stasheff SF, Hedberg-Buenz A, Rudd DS, Batra N, Blodi FR, et al.
Early detection of subclinical visual damage after blast-mediated TBI enables
prevention of chronic visual deficit by treatment with P7C3-S243. Invest
Ophthalmol Vis Sci. (2014) 55:8330–41. doi: 10.1167/iovs.14-15468
15. Bricker-Anthony C, D’Surney L, Lunn B, Hines-Beard J, Jo M, Bernardo-
Colon A, et al. Erythropoietin either prevents or exacerbates retinal damage
from eye trauma depending on treatment timing. Optom Vis Sci. (2017)
94:20–32. doi: 10.1097/OPX.0000000000000898
16. Jiang Y, Pagadala J, Miller DD, Steinle JJ. Insulin-like growth factor-1 binding
protein 3 (IGFBP-3) promotes recovery from trauma-induced expression
of inflammatory and apoptotic factors in retina. Cytokine. (2014) 70:115–9.
doi: 10.1016/j.cyto.2014.07.004
17. Reiner A, Heldt SA, Presley CS, Guley NH, Elberger AJ, Deng Y, et al. Motor,
visual and emotional deficits in mice after closed-head mild traumatic brain
injury are alleviated by the novel CB2 inverse agonist SMM-189. Int J Mol Sci.
(2014) 16:758–87. doi: 10.3390/ijms16010758
18. Wang HC, Choi JH, Greene WA, Plamper ML, Cortez HE, Chavko
M, et al. Pathophysiology of blast-induced ocular trauma with
apoptosis in the retina and optic nerve. Mil Med. (2014) 179:34–40.
doi: 10.7205/MILMED-D-13-00504
19. Zhu Y, Howard JT, Edsall PR, Morris RB, Lund BJ, Cleland JM. Blast exposure
induces ocular functional changes with increasing blast over-pressures in a rat
model. Curr Eye Res. (2019) 44:770–80. doi: 10.1080/02713683.2019.1567791
20. Allen RS, Motz CT, Feola A, Chesler KC, Haider R, Ramachandra
Rao S, et al. Long-term functional and structural consequences of
primary blast overpressure to the eye. J Neurotrauma. (2018) 35:2104–16.
doi: 10.1089/neu.2017.5394
21. Bricker-Anthony C, Hines-Beard J, D’Surney L, Rex TS. Exacerbation of blast-
induced ocular trauma by an immune response. J Neuroinflammation. (2014)
11:192. doi: 10.1186/s12974-014-0192-5
22. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive
phospholipid lysophosphatidic acid is released from activated platelets.
Biochem J. (1993) 291(Pt 3):677–80. doi: 10.1042/bj2910677
23. Moolenaar WH. Lysophosphatidic acid signalling. Curr Opin Cell Biol. (1995)
7:203–10. doi: 10.1016/0955-0674(95)80029-8
24. Crack PJ, Zhang M, Morganti-Kossmann MC, Morris AJ, Wojciak
JM, Fleming JK, et al. Anti-lysophosphatidic acid antibodies improve
traumatic brain injury outcomes. J Neuroinflammation. (2014) 11:37.
doi: 10.1186/1742-2094-11-37
25. Frugier T, Crombie D, Conquest A, Tjhong F, Taylor C, Kulkarni
T, et al. Modulation of LPA receptor expression in the human
brain following neurotrauma. Cell Mol Neurobiol. (2011) 31:569–77.
doi: 10.1007/s10571-011-9650-0
26. Ueda H. LPA receptor signaling as a therapeutic target for radical treatment
of neuropathic pain and fibromyalgia. Pain Manag. (2019) 10:43–53.
doi: 10.2217/pmt-2019-0036
27. Srikanth M, Chew WS, Hind T, Lim SM, Hay NWJ, Lee JHM,
et al. Lysophosphatidic acid and its receptor LPA1 mediate carrageenan
induced inflammatory pain in mice. Eur J Pharmacol. (2018) 841:49–56.
doi: 10.1016/j.ejphar.2018.10.005
28. Shano S, Moriyama R, Chun J, Fukushima N. Lysophosphatidic acid
stimulates astrocyte proliferation through LPA1. Neurochem Int. (2008)
52:216–20. doi: 10.1016/j.neuint.2007.07.004
29. Holtsberg FW, Steiner MR, Keller JN, Mark RJ, Mattson
MP, Steiner SM. Lysophosphatidic acid induces necrosis and
apoptosis in hippocampal neurons. J Neurochem. (1998) 70:66–76.
doi: 10.1046/j.1471-4159.1998.70010066.x
30. Steiner MR, Holtsberg FW, Keller JN, Mattson MP, Steiner SM.
Lysophosphatidic acid induction of neuronal apoptosis and necrosis. Ann N
Y Acad Sci. (2000) 905:132–41. doi: 10.1111/j.1749-6632.2000.tb06545.x
31. Kwon JH, Gaire BP, Park SJ, Shin DY, Choi JW. Identifying lysophosphatidic
acid receptor subtype 1 (LPA1) as a novel factor to modulate microglial
activation and their TNF-alpha production by activating ERK1/2.
Biochim Biophys Acta Mol Cell Biol Lipids. (2018) 1863:1237–45.
doi: 10.1016/j.bbalip.2018.07.015
32. Anliker B, Choi JW, Lin ME, Gardell SE, Rivera RR, Kennedy G, et al.
Lysophosphatidic acid (LPA) and its receptor, LPA1, influence embryonic
schwann cell migration, myelination, cell-to-axon segregation. Glia. (2013)
61:2009–22. doi: 10.1002/glia.22572
33. Sayas CL, Ariaens A, Ponsioen B, Moolenaar WH. GSK-3 is activated by the
tyrosine kinase Pyk2 during LPA1-mediated neurite retraction.Mol Biol Cell.
(2006) 17:1834–44. doi: 10.1091/mbc.e05-07-0688
34. Sun Y, Kim NH, Yang H, Kim SH, Huh SO. Lysophosphatidic acid induces
neurite retraction in differentiated neuroblastoma cells via GSK-3β activation.
Mol Cells. (2011) 31:483–9. doi: 10.1007/s10059-011-1036-0
35. Brault S, Gobeil F Jr, Fortier A, Honore JC, Joyal JS, et al. Lysophosphatidic
acid induces endothelial cell death by modulating the redox environment.
Am J Physiol Regul Integr Comp Physiol. (2007) 292:R1174–83.
doi: 10.1152/ajpregu.00619.2006
36. Yang C, Lafleur J, Mwaikambo BR, Zhu T, Gagnon C, Chemtob S, et al. The
role of lysophosphatidic acid receptor (LPA1) in the oxygen-induced retinal
ganglion cell degeneration. Invest Ophthalmol Vis Sci. (2009) 50:1290–8.
doi: 10.1167/iovs.08-1920
37. Fincher J, Whiteneck C, Birgbauer E. G-protein-coupled receptor cell
signaling pathways mediating embryonic chick retinal growth cone collapse
induced by lysophosphatidic acid and sphingosine-1-phosphate. Dev
Neurosci. (2014) 36:443–53. doi: 10.1159/000364858
38. Dacheva I, Ullmer C, Ceglowska K, Nogoceke E, Hartmann G, Muller S, et al.
Lysophosphatidic acids and autotaxin in retinal vein occlusion. Retina. (2016)
36:2311–18. doi: 10.1097/IAE.0000000000001112
39. Eisenried A, Meidahl ACN, Klukinov M, Tzabazis AZ, Sabbadini RA, Clark
JD, et al. Nervous system delivery of antilysophosphatidic acid antibody
by nasal application attenuates mechanical allodynia after traumatic brain
injury in rats. Pain. (2017) 158:2181–8. doi: 10.1097/j.pain.0000000000
001019
40. Goldshmit Y, Matteo R, Sztal T, Ellett F, Frisca F, Moreno K, et al. Blockage of
lysophosphatidic acid signaling improves spinal cord injury outcomes. Am J
Pathol. (2012) 181:978–92. doi: 10.1016/j.ajpath.2012.06.007
41. Heyburn L, Abutarboush R, Goodrich S, Urioste R, Batuure A, Statz J, et al.
Repeated low-level blast overpressure leads to endovascular disruption and
alterations in TDP-43 and Piezo2 in a rat model of blast TBI. Front Neurol.
(2019) 10:766. doi: 10.3389/fneur.2019.00766
42. Arun P, Wilder DM, Eken O, Urioste R, Batuure A, Sajja S, et al. Long-term
effects of blast exposure: a functional study in rats using an advanced blast
simulator. J Neurotrauma. (2020) 37:647–55. doi: 10.1089/neu.2019.6591
43. Kraemer MP, Mao G, Hammill C, Yan B, Li Y, Onono F, et al. Effects of diet
and hyperlipidemia on levels and distribution of circulating lysophosphatidic
acid. J Lipid Res. (2019) 60:1818–28. doi: 10.1194/jlr.M093096
44. Thomas BB, Seiler MJ, Sadda SR, Coffey PJ, Aramant RB. Optokinetic test to
evaluate visual acuity of each eye independently. J Neurosci Methods. (2004)
138:7–13. doi: 10.1016/j.jneumeth.2004.03.007
45. Prusky GT, Harker KT, Douglas RM, Whishaw IQ. Variation in visual acuity
within pigmented, and between pigmented and albino rat strains. Behav Brain
Res. (2002) 136:339–48. doi: 10.1016/S0166-4328(02)00126-2
46. Kong J, Gouras P. The effect of body temperature on the
murine electroretinogram. Doc Ophthalmol. (2003) 106:239–42.
doi: 10.1023/A:1022988332578
Frontiers in Neurology | www.frontiersin.org 9 December 2020 | Volume 11 | Article 611816
Arun et al. Antibody Therapy Against Eye Injuries
47. Needham CE, Ritzel D, Rule GT,Wiri S, Young L. Blast testing issues and TBI:
experimental models that lead to wrong conclusions. Front Neurol. (2015)
6:72. doi: 10.3389/fneur.2015.00072
48. Kihara Y, Mizuno H, Chun J. Lysophospholipid receptors in drug
discovery. Exp Cell Res. (2015) 333:171–7. doi: 10.1016/j.yexcr.2014.
11.020
49. Ackerman SJ, Park GY, Christman JW, Nyenhuis S, Berdyshev E,
Natarajan V. Polyunsaturated lysophosphatidic acid as a potential
asthma biomarker. Biomark Med. (2016) 10:123–35. doi: 10.2217/bmm.
15.93
50. Logsdon AF, Meabon JS, Cline MM, Bullock KM, Raskind MA, Peskind ER,
et al. Blast exposure elicits blood-brain barrier disruption and repair mediated
by tight junction integrity and nitric oxide dependent processes. Sci Rep.
(2018) 8:11344. doi: 10.1038/s41598-018-29341-6
51. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across
the blood-brain barrier. Neuroimmunomodulation. (1995) 2:241–8.
doi: 10.1159/000097202
Disclaimer: Material has been reviewed by the Walter Reed Army Institute
of Research. There is no objection to its presentation and/or publication. The
opinions or assertions contained herein are the private views of the author, and
are not to be construed as official, or as reflecting true views of the Department of
the Army or the Department of Defense.
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Arun, Rossetti, DeMar, Wang, Batuure, Wilder, Gist, Morris,
Sabbadini and Long. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 10 December 2020 | Volume 11 | Article 611816
